Key considerations in negotiating at-risk contracts

All healthcare stakeholders are aware the day is coming when pharma manufacturers will need to go at-risk in order to secure inclusion of their high-cost drugs in plan formularies.  This shouldn’t be viewed as simply a unilateral opportunity to force price concessions...

From Volume to Healthcare Value: A three-part checklist

How should Medicare providers and ACOs prepare for the shift from fee-for-service to value-based pay? Under a new proposal from the U.S. Department of Health and Human Services (HHS), the shift away from fee-for-service to value-based pay in the public healthcare...